ProCE Banner Activity

What’s New in PrEP? Implications for HIV Prevention in Canada From IAS 2021

Clinical Thought
My key takeaways on data presented from 2 prevention studies at IAS 2021, including Internet-based survey results about long-acting injectable PrEP among American MSM and oral monthly islatravir.

Released: August 18, 2021

Expiration: August 17, 2022

No longer available for credit.

Share

Faculty

Darrell H. S. Tan

Darrell H. S. Tan, MD, FRCPC, PhD

Clinician-Scientist
Division of Infectious Diseases
St. Michael's Hospital
Toronto, Canada

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Gilead Sciences, Inc.

Janssen Therapeutics Division of Janssen Products

Merck Sharp & Dohme Corp.

ViiV Healthcare

Partners

IAS 2021

ProCE Banner

Faculty Disclosure

Primary Author

Darrell H. S. Tan, MD, FRCPC, PhD

Clinician-Scientist
Division of Infectious Diseases
St. Michael's Hospital
Toronto, Canada

Darrell H. S. Tan, MD, FRCPC, PhD, has disclosed that he has received funds for research support from AbbVie, Gilead Sciences, and GlaxoSmithKline.